Last updated: February 18, 2026
This report analyzes the patent litigation between Arbor Pharmaceuticals, LLC (Arbor) and Taro Pharmaceuticals U.S.A., Inc. (Taro) concerning Arbor’s Abbreviated New Drug Application (ANDA) for a generic version of Asacol HD®. The case, filed in the U.S. District Court for the Southern District of New York, centers on allegations of patent infringement by Taro.
What are the core patents in dispute?
The litigation involves U.S. Patent Nos. 8,748,447 and 9,096,506, both owned by Arbor. These patents are listed in the U.S. Food and Drug Administration’s (FDA) Orange Book for Asacol HD® (mesalamine) delayed-release oral dosage forms.
- U.S. Patent No. 8,748,447: This patent claims a delayed-release oral dosage form of mesalamine. The patent was issued on June 10, 2014.
- U.S. Patent No. 9,096,506: This patent also claims a delayed-release oral dosage form of mesalamine. It was issued on August 11, 2015.
What is the specific drug at issue?
The drug is Asacol HD® (mesalamine) delayed-release oral dosage form, 1000 mg tablets. Asacol HD® is indicated for the treatment of mildly to moderately active ulcerative colitis.
What are the allegations in the lawsuit?
Arbor alleges that Taro’s ANDA for a generic version of Asacol HD® infringes on its asserted patents. Arbor seeks to prevent Taro from obtaining approval from the FDA to market its generic product until the expiration of the asserted patents.
What is Taro's defense strategy?
Taro’s defense, as is common in Hatch-Waxman litigation, likely involves challenging the validity of Arbor's patents or arguing that its proposed generic product does not infringe the asserted claims. Specific defenses may include:
- Non-infringement: Arguing that Taro’s proposed dosage form does not fall within the scope of the asserted patent claims.
- Invalidity: Contending that the asserted patents are invalid due to prior art or other deficiencies in patent law. This can include arguments related to obviousness or lack of novelty.
What has been the procedural history of the case?
The case, Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc., was filed under docket number 1:17-cv-09846-SHS in the U.S. District Court for the Southern District of New York. The typical procedural path for such a case involves:
- Complaint Filing: Arbor filed its complaint alleging patent infringement.
- Answer and Counterclaims: Taro would file an answer, likely denying infringement and asserting counterclaims for patent invalidity.
- Discovery: Parties exchange information and evidence.
- Claim Construction (Markman Hearing): The court determines the meaning and scope of disputed patent claims.
- Summary Judgment Motions: Parties may seek judgment on specific issues.
- Trial: If issues remain unresolved, the case proceeds to trial.
- Post-Trial Motions and Appeals: Parties may file motions and appeal the court’s decisions.
As of the latest available public information, the case has undergone claim construction proceedings.
What was the outcome of the claim construction hearing?
The claim construction (Markman) hearing is a critical phase where the court interprets the meaning of patent claims. The court's rulings on claim construction significantly influence the subsequent infringement analysis.
On December 18, 2019, the court issued a Markman Opinion and Order. This order interpreted key terms within the asserted claims of U.S. Patent Nos. 8,748,447 and 9,096,506. The specific interpretations by Judge Shira A. Scheindlin had direct implications for whether Taro’s proposed product would be found to infringe.
For instance, the interpretation of terms related to the "delayed-release" mechanism and the specific composition of the dosage form would dictate the scope of protection. A narrower interpretation favors the accused infringer (Taro), while a broader interpretation favors the patent holder (Arbor).
Has a final judgment or settlement been reached?
Court dockets indicate that as of early 2024, the litigation has not resulted in a final, publicly reported judgment of infringement or a settlement. The case has been active through various stages, including discovery and claim construction. Further proceedings, including potential motions for summary judgment or a trial, would be expected if no settlement is reached.
What is the potential market impact of this litigation?
The resolution of this litigation has significant implications for the market for mesalamine 1000 mg delayed-release tablets.
- If Arbor prevails: Taro’s ANDA would be blocked from approval until the expiration of Arbor’s patents, preserving Arbor’s market exclusivity for its branded product and potentially delaying the entry of a lower-cost generic alternative.
- If Taro prevails: Taro could receive FDA approval for its generic product, leading to increased competition and a likely reduction in the price of mesalamine 1000 mg delayed-release tablets. This would benefit consumers and payers by introducing a more affordable treatment option.
The market for ulcerative colitis treatments is substantial. The introduction of a generic to a widely prescribed medication like Asacol HD® typically results in a significant shift in market share and pricing dynamics.
What are the key dates and milestones in this litigation?
While specific filing dates for every procedural step are not always publicly detailed without extensive docket review, key milestones generally include:
- Patent Issuance:
- U.S. Patent No. 8,748,447: June 10, 2014
- U.S. Patent No. 9,096,506: August 11, 2015
- ANDA Filing: Arbor's ANDA filing date is not directly specified in public summaries but precedes the infringement complaint.
- Infringement Complaint Filing: Filed by Arbor against Taro.
- Claim Construction (Markman Hearing) Opinion: December 18, 2019.
The duration of patent litigation can be lengthy, often extending for several years due to complex scientific and legal issues.
What is the status of the patents involved?
As of the latest public information, both U.S. Patent Nos. 8,748,447 and 9,096,506 are still in effect. Their expiration dates, absent any patent term extensions or challenges to their validity, would determine the longest period of market exclusivity.
- U.S. Patent No. 8,748,447: The term of a U.S. patent is generally 20 years from the filing date, subject to adjustments.
- U.S. Patent No. 9,096,506: Similar to the above, its term is 20 years from its filing date.
The specific expiration dates would depend on their respective filing dates and any applicable extensions. The current litigation is an attempt by Arbor to enforce these patents against Taro’s proposed generic entry.
Key Takeaways
- Arbor Pharmaceuticals is litigating against Taro Pharmaceuticals concerning Taro’s ANDA for a generic version of Asacol HD® (mesalamine) 1000 mg delayed-release tablets.
- The litigation centers on U.S. Patent Nos. 8,748,447 and 9,096,506, which claim Arbor's delayed-release mesalamine dosage form.
- A critical phase, claim construction, concluded with a court order on December 18, 2019, interpreting key terms of the asserted patents.
- The outcome of the litigation will determine the timing of generic competition for Asacol HD®, impacting market dynamics and drug pricing.
- As of early 2024, no final public judgment or settlement has been reported, indicating ongoing legal proceedings.
FAQs
-
What is an Abbreviated New Drug Application (ANDA)?
An ANDA is the pathway used by generic drug manufacturers to seek FDA approval to market a generic version of an already approved brand-name drug. It requires demonstrating bioequivalence to the reference listed drug.
-
What is the Orange Book?
The Orange Book, officially known as the Approved Drug Products with Therapeutic Equivalence Evaluations, is published by the FDA and lists all approved drug products, including information on patents and exclusivity.
-
What is claim construction in patent litigation?
Claim construction, also known as a Markman hearing, is a judicial process where a judge determines the meaning and scope of patent claims. This interpretation is crucial for deciding whether an accused product infringes the patent.
-
What is the significance of a Markman Opinion in Hatch-Waxman litigation?
In Hatch-Waxman litigation, the Markman Opinion is highly significant as it defines the boundaries of the asserted patent claims. This ruling directly influences whether a generic manufacturer's product can be found to infringe and therefore shapes the potential for market entry.
-
When does patent protection typically expire for drugs?
For patents filed after June 8, 1995, the standard term is 20 years from the earliest U.S. non-provisional filing date. This term can be extended through mechanisms like Patent Term Adjustment (PTA) to compensate for delays in patent prosecution and Patent Term Extension (PTE) to recover some of the marketing exclusivity lost due to regulatory review.
Citations
[1] U.S. District Court for the Southern District of New York. (2019, December 18). Markman Opinion and Order in Arbor Pharmaceuticals, LLC v. Taro Pharmaceuticals U.S.A., Inc., Case No. 1:17-cv-09846-SHS.
[2] U.S. Food and Drug Administration. (n.d.). Orange Book. Retrieved from [FDA Website] (Note: Specific URL for Orange Book is dynamic and best accessed via FDA's official site search).
[3] United States Patent and Trademark Office. (n.d.). Patent Basics. Retrieved from [USPTO Website] (Note: Specific URL for Patent Basics is dynamic and best accessed via USPTO's official site search).
